treatment-resistant depression
Articles tagged with “treatment-resistant depression”
Compass Pathways: Extra COMP360 Dose Extends Relief to 1 Year
Compass Pathways reports 52-week open-label data from its COMP005 trial showing a second COMP360 psilocybin dose extended benefit. Here's what patients should know.
Why Ketamine Therapy Is Booming Across America
Ketamine use is surging across the U.S. for reasons beyond the drug itself. Here's what patients and families evaluating ketamine therapy need to understand.
GH Research Reports Phase 2 Results for Depression Treatment
GH Research reports Phase 2 results for GH001 in postpartum and treatment-resistant depression. Analysis of implications for ketamine patients.
FDA Clears Trial Pairing Ketamine Follow-Up Drug With TMS
The FDA cleared the MIND1 trial testing NRX-101 with robotic TMS for treatment-resistant depression and suicidality. What ketamine patients should know.
FDA Fast-Tracks Psychedelics for Depression, PTSD, and AUD
The FDA is accelerating psychedelic drug development for treatment-resistant depression, PTSD, and AUD. What it means for patients exploring ketamine therapy.
Side Effects & Dropout Rates: New Data on Ketamine for TRD
New clinical guidance on NMDA antagonist side effects and dropout rates offers practical insight for patients considering ketamine therapy for TRD.
Why Patients Quit NMDA Therapy, And What Providers Should Do
New clinical review urges faster dose optimization and earlier switching between NMDA therapies for treatment-resistant depression. Here's what it means for patients.
When to Push for Stronger TRD Treatments, Per Experts
Psychiatric Times highlights underuse of highly effective TRD treatments. Here's what this means if you or a loved one is stuck in a cycle of failed antidepressants.
NMDA Side Effects: What Dropout Rates Mean for Patients
New clinical guidance on NMDA antagonist side effects and dropout rates offers practical insights for patients considering ketamine or esketamine therapy.
Ketamine Side Effects: What New Clinical Data Reveals
New clinical analysis examines side effect profiles and discontinuation rates for ketamine and esketamine. Here's what treatment-resistant depression patients should know.
BPL-003 Shows Lasting Relief in Treatment-Resistant Depression
New phase 2a data on BPL-003 shows sustained symptom reduction in treatment-resistant depression. What patients should know about this emerging therapy.
Ketamine Side Effects: What New Data Tells Patients
A new clinical review examines side effect profiles and discontinuation rates for NMDA antagonists like ketamine and esketamine. Here's what patients should know.
Ketamine Side Effects: What New Data Means for Patients
New clinical guidance on NMDA antagonist side effects and discontinuation rates gives patients and families sharper questions to ask before starting ketamine therapy.
How Doctors Choose Ketamine vs. Other TRD Treatments
New clinical guidance explains how psychiatrists choose between esketamine, ketamine, and brain stimulation for treatment-resistant depression patients.
Esketamine's Role in Treatment-Resistant Depression Care
Where esketamine (Spravato) sits in 2026 treatment-resistant depression care: FDA-approved indications, response rates after SSRI failure, access barriers, and how it compares to generic IV and at-home options.
New Ketamine Nasal Spray Shows Lasting Depression Relief
Phase 2a trial results for BPL-003, a ketamine-based nasal spray for treatment-resistant depression, show sustained symptom reduction. Here's what it means.
Overcoming Treatment-Resistant Depression with Ketamine Therapy
Overcoming treatment-resistant depression with ketamine, a patient journey through failed medications, finding hope, and experiencing rapid relief with ketamine.
Ketamine Therapy vs. ECT: Comparing Two Breakthrough Depression Treatments
How do ketamine therapy and ECT compare for treatment-resistant depression? Side effects, response time, cost, and which treatment fits your situation.
Need help or want to reach readers?
Have a correction, provider question, or advertising inquiry? Reach the editorial team.